CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Prescott, AZ
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).